Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.

In addition to genetic events, a variety of epigenetic events have been widely reported to contribute to the onset of many diseases including cancer. DNA methylation and histone modifications (such as acetylation, methylation, sumoylation, and phosphorylation) involving chromatin remodelling are among the most studied epigenetic mechanisms for regulation of gene expression leading, when altered, to some diseases. Epigenetic therapy tries to reverse the aberrations followed to the disruption of the balance of the epigenetic signalling ways through the use of both natural compounds and synthetic molecules, active on specific epi-targets. Such epi-drugs are, for example, inhibitors of DNA methyltransferases, histone deacetylases, histone acetyltransferases, histone methyltransferases, and histone demethylases. In this review we will focus on the chemical aspects of such molecules, joined to their effective (or potential) application in cancer therapy.

[1]  C. Bradbury,et al.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors , 2005, Leukemia.

[2]  Sylvain Lefebvre,et al.  MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo , 2008, Molecular Cancer Therapeutics.

[3]  N. L. La Thangue,et al.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds. , 2001, Journal of cell science.

[4]  M. Binaschi,et al.  Histone deacetylase inhibitors: from bench to clinic. , 2008, Journal of medicinal chemistry.

[5]  D. Sinclair,et al.  Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. , 2005, Journal of medicinal chemistry.

[6]  D. Qian,et al.  Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589 , 2006, Clinical Cancer Research.

[7]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[8]  P. Atadja,et al.  Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. , 2006, Blood.

[9]  J. Denu.  The Sir 2 family of protein deacetylases. , 2005, Current opinion in chemical biology.

[10]  Robert Brown,et al.  A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[11]  C. Sardet,et al.  Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene , 2006, Proceedings of the National Academy of Sciences.

[12]  Aaron T. Smith,et al.  Quinoline derivative MC 1626 , a putative GCN 5 histone 3 acetyltransferase ( HAT ) inhibitor , exhibits HAT-4 independent activity against Toxoplasma gondii 5 6 7 , 2006 .

[13]  M. Grunstein,et al.  All four core histone N‐termini contain sequences required for the repression of basal transcription in yeast. , 1996, The EMBO journal.

[14]  O. Wiest,et al.  Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. , 2005, Journal of medicinal chemistry.

[15]  C. Chen,et al.  JMJD3 is a histone H3K27 demethylase , 2007, Cell Research.

[16]  A. Conney,et al.  Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. , 1992, Carcinogenesis.

[17]  S. Baylin,et al.  Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes , 2007, Proceedings of the National Academy of Sciences.

[18]  M. Jeffers,et al.  Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer , 2008, International journal of cancer.

[19]  L. Guarente,et al.  Sir2 links chromatin silencing, metabolism, and aging. , 2000, Genes & development.

[20]  N. Tsuji,et al.  Trichostatin C, a glucopyranosyl hydroxamate. , 1978, The Journal of antibiotics.

[21]  J. Michaeli,et al.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. , 1992, Blood.

[22]  L. Altucci,et al.  Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. , 2006, Journal of medicinal chemistry.

[23]  S. Steinberg,et al.  Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma , 2006, Clinical Cancer Research.

[24]  M. Simpson,et al.  Structural Insights into Histone Demethylation by JMJD2 Family Members , 2006, Cell.

[25]  J. Prous,et al.  Gateways to Clinical Trials. June 2002. , 2002, Methods and findings in experimental and clinical pharmacology.

[26]  Sardet Claude,et al.  コアクチベータと会合したアルギニンメチルトランスフェラーゼ1(CARM1)はサイクリンE1遺伝子の正の制御剤である , 2006 .

[27]  Randall W King,et al.  Small Molecule Regulators of Protein Arginine Methyltransferases* , 2004, Journal of Biological Chemistry.

[28]  M. Nishiyama,et al.  FK 228 ( Depsipeptide ) as a Natural Prodrug That Inhibits Class I Histone Deacetylases 1 , 2002 .

[29]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[30]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[32]  Y. Ouchi,et al.  Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras–MAPK signaling in human cancer cells , 2006, Oncogene.

[33]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[34]  S. Schreiber,et al.  Identification of a Class of Small Molecule Inhibitors of the Sirtuin Family of NAD-dependent Deacetylases by Phenotypic Screening* , 2001, The Journal of Biological Chemistry.

[35]  O. Politz,et al.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent. , 2007, The international journal of biochemistry & cell biology.

[36]  R. Abagyan,et al.  Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. , 2007, Science.

[37]  M. Lübbert,et al.  DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.

[38]  R. Smart,et al.  Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. , 1988, Cancer research.

[39]  Andrew J. Bannister,et al.  Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity , 2005, Molecular Cancer Therapeutics.

[40]  G. Curt,et al.  A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). , 1985, Cancer research.

[41]  Udaykumar Ranga,et al.  Curcumin, a Novel p300/CREB-binding Protein-specific Inhibitor of Acetyltransferase, Represses the Acetylation of Histone/Nonhistone Proteins and Histone Acetyltransferase-dependent Chromatin Transcription* , 2004, Journal of Biological Chemistry.

[42]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Yoshida,et al.  Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. , 1990, The Journal of antibiotics.

[44]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Beisler.  Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. , 1978, Journal of medicinal chemistry.

[46]  R A Rifkind,et al.  Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Kouzarides,et al.  DNA methyltransferases get connected to chromatin. , 2002, Trends in genetics : TIG.

[48]  P. Atadja,et al.  Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation , 2007, Clinical Cancer Research.

[49]  J. Prous,et al.  Gateways to clinical trials. , 2006, Methods and findings in experimental and clinical pharmacology.

[50]  R. Jaenisch,et al.  DNA methylation, genomic imprinting, and mammalian development. , 1993, Cold Spring Harbor symposia on quantitative biology.

[51]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[52]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[53]  S. Vandenberg,et al.  Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas , 2005, Molecular Cancer Therapeutics.

[54]  R. Jaenisch,et al.  DNA hypomethylation can activate Xist expression and silence X-linked genes. , 1996, Genes & development.

[55]  M. Grever,et al.  The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.

[56]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[57]  Manel Esteller,et al.  Cross‐Talk between Aging and Cancer , 2007, Annals of the New York Academy of Sciences.

[58]  B. Aggarwal,et al.  Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. , 2005, Biochemical pharmacology.

[59]  S. Schreiber,et al.  CoREST is an integral component of the CoREST- human histone deacetylase complex. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P. Distefano,et al.  Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. , 2005, Journal of medicinal chemistry.

[61]  M. L. Eidinoff,et al.  Growth inhibition of a human tumor cell strain by 5-fluoro-2-deoxyuridine: time parameters for subsequent reversal by thymidine. , 1959, Cancer research.

[62]  A. M. Salazar,et al.  Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[63]  A. Nudelman,et al.  Derivatives of butyric acid as potential anti‐neoplastic agents , 1991, International journal of cancer.

[64]  P. Trojer,et al.  A novel arginine methyltransferase inhibitor with cellular activity. , 2007, Bioorganic & medicinal chemistry letters.

[65]  S. Moolgavkar.  Cancer Models , 2019, Frontiers Research Topics.

[66]  Frank Lyko,et al.  Discovery of two novel, small-molecule inhibitors of DNA methylation. , 2006, Journal of medicinal chemistry.

[67]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[68]  M. Janicot,et al.  R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies , 2007, British Journal of Cancer.

[69]  寺尾 泰久.  Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells , 2002 .

[70]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[71]  J. Herman,et al.  A systematic profile of DNA methylation in human cancer cell lines. , 2003, Cancer research.

[72]  Kun-Tsan Lin,et al.  High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. , 1981, Journal of pharmaceutical sciences.

[73]  Yusuke Nakamura,et al.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells , 2004, Nature Cell Biology.

[74]  D. Sinclair,et al.  Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1* , 2002, The Journal of Biological Chemistry.

[75]  Dudley Lamming,et al.  MicroReview: Small molecules that regulate lifespan: evidence for xenohormesis , 2004, Molecular microbiology.

[76]  C. Walsh,et al.  Transcription of IAP endogenous retroviruses is constrained by cytosine methylation , 1998, Nature Genetics.

[77]  Kelly M. McGarvey,et al.  Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. , 2006, Cancer research.

[78]  R. Kuttan,et al.  Potential anticancer activity of turmeric (Curcuma longa). , 1985, Cancer letters.

[79]  Anu J. Tervo,et al.  N-(3-(4-Hydroxyphenyl)-propenoyl)-amino acid tryptamides as SIRT2 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[80]  T. Suzuki,et al.  Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. , 1999, Journal of medicinal chemistry.

[81]  L. Ngo,et al.  Potent cytodifferentiating agents related to hexamethylenebisacetamide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[83]  L. Grochow,et al.  A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[84]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[85]  C. Kunick,et al.  Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. , 2006, Journal of medicinal chemistry.

[86]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[87]  A. Mai,et al.  A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. , 2005, Biochemical pharmacology.

[88]  R. Schüle,et al.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. , 2006, Cancer research.

[89]  Yang Shi,et al.  Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases , 2006, Cell.

[90]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[91]  K. Bible,et al.  Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. , 2007, Blood.

[92]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[93]  N. Pavletich,et al.  Structure of the histone deacetylase SIRT2 , 2001, Nature Structural Biology.

[94]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[95]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[96]  T. Habuchi,et al.  Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. , 2007, Oncology reports.

[97]  A. Bird.  DNA methylation patterns and epigenetic memory. , 2002, Genes & development.

[98]  K. Mori,et al.  Synthesis of trichostatin a, a potent differentiation inducer of friend leukemic cells, and its antipode , 1988 .

[99]  D. Hallahan,et al.  Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. , 2006, Cancer research.

[100]  S. Berger,et al.  Catalytic Mechanism and Function of Invariant Glutamic Acid 173 from the Histone Acetyltransferase GCN5 Transcriptional Coactivator* , 1999, The Journal of Biological Chemistry.

[101]  P. Trojer,et al.  Target-based approach to inhibitors of histone arginine methyltransferases. , 2007, Journal of medicinal chemistry.

[102]  Mark T Bedford,et al.  Arginine methylation an emerging regulator of protein function. , 2005, Molecular cell.

[103]  B. Aggarwal,et al.  Role of curcumin in cancer therapy. , 2007, Current problems in cancer.

[104]  M. Lübbert,et al.  Current status of epigenetic treatment in myelodysplastic syndromes , 2008, Annals of Hematology.

[105]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[106]  Lang Li,et al.  Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen‐independent status , 2004, Cancer.

[107]  N. L. La Thangue,et al.  Chromatin control and cancer-drug discovery: realizing the promise. , 2006, Drug discovery today.

[108]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[109]  Byron H. Lee,et al.  Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1* , 2005, Journal of Biological Chemistry.

[110]  Manel Esteller,et al.  Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. , 2003, Cancer research.

[111]  Karl Mechtler,et al.  Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.

[112]  M. Loda,et al.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? , 2002, Cancer cell.

[113]  J. Hess.  MLL: a histone methyltransferase disrupted in leukemia. , 2004, Trends in molecular medicine.

[114]  Alexander V. Lyubimov,et al.  Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine , 2005, Clinical Cancer Research.

[115]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[116]  Sanjeev Banerjee,et al.  Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation , 2002, Oncogene.

[117]  J. Holland,et al.  Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  P. Atadja,et al.  N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.

[119]  L. Altucci,et al.  epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. , 2008, Journal of medicinal chemistry.

[120]  T. Richmond,et al.  Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.

[121]  P. Finn,et al.  Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. , 2008, The Biochemical journal.

[122]  D. Reinberg,et al.  Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[123]  Decitabine in Myelodysplastic Syndromes , 2005 .

[124]  D. M. Schmidt,et al.  trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. , 2007, Biochemistry.

[125]  S. Gore,et al.  DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. , 2008, Seminars in hematology.

[126]  L. Ellis,et al.  Targeting tumor angiogenesis with histone deacetylase inhibitors. , 2009, Cancer letters.

[127]  Kelly M. McGarvey,et al.  Inhibition of SIRT1 Reactivates Silenced Cancer Genes without Loss of Promoter DNA Hypermethylation , 2006, PLoS genetics.

[128]  N. Colburn,et al.  Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor-κB/p65 DNA Binding , 2005, Molecular Cancer Research.

[129]  H. Erdjument-Bromage,et al.  Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.

[130]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[131]  N. Colburn,et al.  Histone Deacetylase Inhibition Down-Regulates Cyclin D 1 Transcription by Inhibiting Nuclear Factor-K B / p 65 DNA Binding , 2005 .

[132]  Frank Lyko,et al.  Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.

[133]  Ralf Schirrmacher,et al.  Synthesis and in vitro evaluation of biotinylated RG108: a high affinity compound for studying binding interactions with human DNA methyltransferases. , 2006, Bioconjugate chemistry.

[134]  Wei Gu,et al.  Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.

[135]  Eric Verdin,et al.  Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. , 2008, Journal of medicinal chemistry.

[136]  T. Bestor,et al.  Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.

[137]  D. Santi,et al.  Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[138]  Antoine H. F. M. Peters,et al.  LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription , 2005, Nature.

[139]  Julie A Hong,et al.  Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells , 2007, Cancer journal.

[140]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[141]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[142]  Yun-Jin Jung,et al.  Curcumin is an inhibitor of p300 histone acetylatransferase. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).

[143]  J. Issa,et al.  Decitabine dosing schedules. , 2005, Seminars in hematology.

[144]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[145]  L. Guarente,et al.  The Sir2 family of protein deacetylases. , 2004, Annual review of biochemistry.

[146]  M. Diccianni,et al.  The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. , 2002, Blood.

[147]  P. Thompson,et al.  In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. , 2008, Journal of the American Chemical Society.

[148]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[149]  O. Wiest,et al.  On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. , 2004, Journal of medicinal chemistry.

[150]  L. Altucci,et al.  Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors , 2007, ChemMedChem.

[151]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[152]  K. Nagashima,et al.  A new antifungal antibiotic, trichostatin. , 1976, The Journal of antibiotics.

[153]  Ruben Abagyan,et al.  Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.

[154]  A. Bhagwat,et al.  The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. , 1995, The Biochemical journal.

[155]  W. Sippl,et al.  Structure–Activity Studies on Suramin Analogues as Inhibitors of NAD+‐Dependent Histone Deacetylases (Sirtuins) , 2007, ChemMedChem.

[156]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[157]  M. K. Pflum,et al.  Isoform-selective histone deacetylase inhibitors. , 2008, Chemical Society reviews.

[158]  B. Aggarwal,et al.  Anticancer potential of curcumin: preclinical and clinical studies. , 2003, Anticancer research.

[159]  R. Roeder,et al.  HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. , 2000, Molecular cell.

[160]  Tapas K. Kundu,et al.  Small Molecule Modulators of Histone Acetyltransferase p300* , 2003, Journal of Biological Chemistry.

[161]  Aaron T. Smith,et al.  Quinoline Derivative MC1626, a Putative GCN5 Histone Acetyltransferase (HAT) Inhibitor, Exhibits HAT-Independent Activity against Toxoplasma gondii , 2006, Antimicrobial Agents and Chemotherapy.

[162]  S. Hirohashi,et al.  Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. , 2007, Carcinogenesis.

[163]  Lee Baker,et al.  Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator , 2007, Cancer cell.

[164]  Axel Imhof,et al.  Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9 , 2005, Nature chemical biology.

[165]  L. Grochow,et al.  A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[166]  M. Yoshida,et al.  Effects of trichostatins on differentiation of murine erythroleukemia cells. , 1987, Cancer research.

[167]  Athanassios Giannis,et al.  Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. , 2004, Angewandte Chemie.

[168]  T. Kundu,et al.  Polyisoprenylated Benzophenone, Garcinol, a Natural Histone Acetyltransferase Inhibitor, Represses Chromatin Transcription and Alters Global Gene Expression* , 2004, Journal of Biological Chemistry.

[169]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[170]  C. Allis,et al.  Chromatin remodeling and cancer, Part I: Covalent histone modifications. , 2007, Trends in molecular medicine.

[171]  M. Lübbert,et al.  Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). , 2006, Leukemia research.

[172]  Takayoshi Suzuki,et al.  2‐Anilinobenzamides as SIRT Inhibitors , 2006, ChemMedChem.

[173]  Ni Ai,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. , 2003, Cancer research.

[174]  Silvio Massa,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[175]  M. Machius,et al.  Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. , 2007, Biochemistry.

[176]  R. Notari,et al.  Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. , 1975, Journal of pharmaceutical sciences.

[177]  C. Britten,et al.  A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[178]  L. Altucci,et al.  Acute myeloid leukemia: therapeutic impact of epigenetic drugs. , 2005, The international journal of biochemistry & cell biology.

[179]  J. Workman,et al.  Histone acetylation and chromatin remodeling: which comes first? , 2002, Molecular genetics and metabolism.

[180]  C. Langford,et al.  Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. , 2007, Genome research.

[181]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[182]  Xiaofeng Jiang,et al.  Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation , 2006, FEBS letters.

[183]  R. DePinho,et al.  Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. , 2006, Cancer research.

[184]  D. Gottschling,et al.  Identification of a small molecule inhibitor of Sir2p , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[185]  D. Qian,et al.  Antitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models , 2007, The Prostate.

[186]  H. Bartsch,et al.  Characterization of alkyl phenols in cashew (Anacardium occidentale) products and assay of their antioxidant capacity. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[187]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[188]  Z. Malik,et al.  The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. , 2007, Cancer letters.